Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update March 8, 2024
Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 November 6, 2023
Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting November 1, 2023
Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update August 14, 2023
Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update May 12, 2023
